Pharmacogenomic Determinants of the Cardiovascular Effects of Dalcetrapib

Circulation: Cardiovascular Genetics

Volumn 8, Issue 2, 2015, Pages 372-382

  Tardif, Jean Claude ^a,b   Rheaúme, Eric ^a,b   Lemieux Perreault, Louis Philippe ^a,b   Grégoire, Jean C ^a,b   Feroz Zada, Yassamin ^a,b   Asselin, Géraldine ^a,b   Provost, Sylvie ^a,b   Barhdadi, Amina ^a,b   Rhainds, David ^a   L'Allier, Philippe L ^a,b   Ibrahim, Reda ^a,b   Upmanyu, Ruchi ^f   Niesor, Eric J ^f   Benghozi, Reneé ^f   Suchankova, Gabriela ^f   Laghrissi Thode, Fouzia ^f   Guertin, Marie Claude ^a,c   Olsson, Anders G ^d   Mongrain, Ian ^a,b   Schwartz, Gregory G ^e   Dubé, Marie Pierre ^a,b   more..

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Montreal Health Innovations Coordinating Center (MHICC)   (Canada)

^d Stockholm Heart Center   (Sweden)

^e UNIVERSITY OF COLORADO   (United States)

^f F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

cholesteryl ester transfer protein; dalcetrapib; high density lipoproteins; pharmacogenetics

Indexed keywords

DALCETRAPIB; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ADENYLATE CYCLASE; ADENYLATE CYCLASE 9; THIOL DERIVATIVE;

ADCY9 GENE; ADULT; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CHOLESTEROL BLOOD LEVEL; CHROMOSOME 16; CONTROLLED STUDY; DIABETES MELLITUS; ECHOGRAPHY; FEMALE; GENE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART ARREST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PATIENT HISTORY OF CORONARY ARTERY BYPASS GRAFT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; UNSTABLE ANGINA PECTORIS; AGED; ATHEROSCLEROSIS; CLINICAL TRIAL; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; MULTICENTER STUDY; PHARMACOGENETICS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADENYLYL CYCLASES; AGED; ATHEROSCLEROSIS; CAROTID INTIMA-MEDIA THICKNESS; CHROMOSOMES, HUMAN, PAIR 16; FEMALE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SULFHYDRYL COMPOUNDS;

EID: 84928798085     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000663     Document Type: Article

References (21)

1. HPS2-THRIVE Collaborative Group. Hps2-Thrive randomized placebocontrolled trial in 25 673 high-risk patients of er niacin/laropiprant: Trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279-1291.
2. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-2267.
3. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122. doi: 10.1056/NEJMoa0706628.
4. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099. doi: 10.1056/NEJMoa1206797.
5. Arsenault BJ, Boekholdt SM, Tardif JC, Kastelein JJ. De-risking the clinical development of cholesteryl ester transfer protein inhibitors: how much is good enough? Eur Heart J. 2012;33:1548-1550. doi: 10.1093/eurheartj/ehr408.
6. Rhainds D, Arsenault BJ, Brodeur MR, Tardif JC. An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels. Future Cardiol. 2012;8:513-531. doi: 10.2217/fca.12.25.
7. Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto M, Shih DM, et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest. 2011;121:2693-2708. doi: 10.1172/JCI42946.
8. Tardif JC, Lesage F, Harel F, Romeo P, Pressacco J. Imaging biomarkers in atherosclerosis trials. Circ Cardiovasc Imaging. 2011;4:319-333. doi: 10.1161/CIRCIMAGING.110.962001.
9. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34:290-296. doi: 10.1159/000343145.
10. Howie B, Marchini J, Stephens M. Genotype imputation with thousands of genomes. G3 (Bethesda). 2011;1:457-470. doi: 10.1534/g3.111.001198.
11. Delaneau O, Marchini J, Zagury JF. A linear complexity phasing method for thousands of genomes. Nat Methods. 2012;9:179-181. doi: 10.1038/nmeth.1785.
12. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. Am J Hum Genet. 2011;89:82-93. doi: 10.1016/j.ajhg.2011.05.029.
13. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32:361-369. doi: 10.1002/gepi.20310.
14. Cumbay MG, Watts VJ. Novel regulatory properties of human type 9 adenylate cyclase. J Pharmacol Exp Ther. 2004;310:108-115. doi: 10.1124/jpet.104.065748.
15. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the bronchodilator response to inhaled combination therapy. J Clin Pharm Ther. 2011;36:399-405. doi: 10.1111/j.1365-2710.2010.01196.x.
16. Berndt SI, Gustafsson S, Mägi R, Ganna A, Wheeler E, Feitosa MF, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45:501-512. doi: 10.1038/ng.2606.
17. Ray KK, Ditmarsch M, Kallend D, Niesor EJ, Suchankova G, Upmanyu R, et al; dal-ACUTE Investigators. The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial. Eur Heart J. 2014;35:1792-1800. doi: 10.1093/eurheartj/ehu105.
18. Pontier SM, Percherancier Y, Galandrin S, Breit A, Galés C, Bouvier M. Cholesterol-dependent separation of the beta2-adrenergic receptor from its partners determines signaling efficacy: insight into nanoscale organization of signal transduction. J Biol Chem. 2008;283:24659-24672. doi: 10.1074/jbc.M800778200.
19. Haidar B, Denis M, Krimbou L, Marcil M, Genest J Jr. cAMP induces ABCA1 phosphorylation activity and promotes cholesterol efflux from fibroblasts. J Lipid Res. 2002;43:2087-2094.
20. See RH, Caday-Malcolm RA, Singaraja RR, Zhou S, Silverston A, Huber MT, et al. Protein kinase A site-specific phosphorylation regulates ATPbinding cassette A1 (ABCA1)-mediated phospholipid efflux. J Biol Chem. 2002;277:41835-41842. doi: 10.1074/jbc.M204923200.
21. Buchanan CC, Torstenson ES, Bush WS, Ritchie MD. A comparison of cataloged variation between International HapMap Consortium and 1000 Genomes Project data. J Am Med Inform Assoc. 2012;19:289-294. doi: 10.1136/amiajnl-2011-000652.